Analytical performance of the Lumipulse® G β‐Amyloid 1‐40 Plasma and Lumipulse® G β‐Amyloid 1‐42 Plasma RUO assays

Current research indicates that plasma β‐amyloid1‐42/β‐amyloid1‐40 ratio has the potential for application in clinical settings and clinical trials to predict brain β‐amyloid burden. It could reduce the number of lumbar punctures (for CSF biomarker testing) or Aβ‐PET scans in light of clinical trial recruitment and could serve as a tool to evaluate target engagement and efficacy of disease‐modifying drugs. The aim of the current study was to demonstrate the analytical performance of the newly developed Lumipulse G β‐Amyloid 1‐40 Plasma and Lumipulse G β‐Amyloid 1‐42 Plasma RUO assays.